<DOC>
	<DOCNO>NCT00109382</DOCNO>
	<brief_summary>Current management patient TIA ( transient ischemic attack ) minor stroke include prompt investigation treatment day week event . However , new evidence show patient high risk stroke first day TIA , 50 % stroke happen three month follow TIA occur within 48-72 hour . To date , evidence guide physician safely reduce risk . The FASTER trial focus initial period high risk , start patient stroke prevention treatment hour follow TIA minor stroke . The drug test show effective similar set cardiology , reduce recurrent cardiac event patient unstable angina commence speed event . All patient aspirin . The trial see add another drug , clopidogrel , additional benefit reduce number stroke TIA minor stroke within three month TIA minor stroke . It also look early introduction simvastatin , cholesterol lower therapy , reduces stroke TIA minor stroke , addition clopidogrel . The final aim trial ensure treatment safe used population patient .</brief_summary>
	<brief_title>Fast Assessment Stroke Transient Ischemic Attack Prevent Early Recurrence ( FASTER )</brief_title>
	<detailed_description>The Fast Assessment Stroke Transient ischemic attack prevent Early Recurrence ( FASTER ) randomize clinical trial design investigate effect hyper-acute initiation stroke prevention treatment patient minor stroke transient ischemic attack ( TIA ) . This group individual recognize high risk recurrent event . Johnston et al . ( 2000 ) first suggest risk stroke TIA front-loaded first day . This confirm elsewhere Lovett et al . ( 2003 ) show Oxfordshire Community Stroke Project 7-day risk recurrent stroke 8.6 % , 30-day risk 12.0 % . These finding similarly find Oxford Vascular Study ; 8.0 % 11.5 % respectively recurrent event ( Coull et al. , 2004 ) . The NASCET ( North American Symptomatic Carotid Endarterectomy Trial ) study also support find high risk early recurrent stroke . 8.5 % patient hemispheric TIA suffer recurrent stroke within one week rise 20 % 90-days ( Eliasziw et al. , 2004 ) . This data suggest patient carotid stenosis high risk early recurrent stoke . Only one four patient acute ischemic stroke present within three hour symptom onset treat t-PA ( Barber et al. , 2001 ) . The common reason exclusion treatment patient 's deficit mild treatment completely resolve thereby merit risk treatment tPA . These patient high risk early recurrence . The clinical imperative identify hyper-acute treatment strategy minimize risk . FASTER double blind , randomize control trial 2x2 factorial design patient follow 90-days . Patients randomize within 24 hour symptom onset one four possible treatment arm : - Aspirin - Aspirin Clopidogrel - Aspirin Simvastatin - Aspirin Clopidogrel Simvastatin Study Hypotheses A . A rapid commencement clopidogrel plus aspirin within 24 hour acute TIA minor stroke effective aspirin reduce 90-day risk stroke absolute difference 2 % . B . A rapid commencement simvastatin plus aspirin within 24 hour acute TIA minor stroke effective aspirin reduce 90-day risk stroke absolute difference 2 % . C. A rapid commencement clopidogrel plus aspirin plus simvastatin within 24 hour acute TIA minor stroke effective aspirin alone reduce 90-day risk stroke absolute difference 4 % . D. The incidence adverse event different among treatment group .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Ischemic Attack , Transient</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Patients TIA minor acute ischemic stroke ( NIHSS &lt; 4 time randomization ) must NOT candidate acute thrombolysis acute intervention indicate current standard care Aged 40 year old Patients : ( ) weakness time TIA/minor stroke and/or language disturbance time TIA/minor stroke ; ( b ) duration neurological deficit ( TIA ) &gt; 5 minute Patients randomize within 24 hour symptom onset . Symptom onset define `` last see well '' principle Patients must provide write , inform consent participate FASTER trial . Patients pure sensory symptom , pure vertigo dizziness , pure ataxia pure visual loss Patients thrombolysis acute intervention indicate current standard care Patients currently statin therapy , antiplatelet therapy ( include aspirin ) , longterm nonsteroidal antiinflammatory drug ( NSAIDs COX inhibitor ) , anticoagulation Patients opinion site Investigator , commence statin therapy Patients neurological deficit due intracranial hemorrhage ( intracranial hemorrhage , subarachnoid hemorrhage , subdural hematoma , epidural hematoma ) , tumor , infection find consistent acute brain ischemia cause present symptom Presumed cardiac source embolus ( e.g . atrial fibrillation , prosthetic cardiac valve , known/suspected endocarditis ) Patient concomitant acute coronary syndrome ( acute myocardial infarction unstable angina ) Modified Rankin Score 3 ( premorbid historical assessment ) Patients qualify event due complication cerebral angiography , revascularization procedure trauma Uncontrolled hypertension baseline ( systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg ) , malignant hypertension define brain plus acute organ involvement due acute hypertension Women breastfeed pregnant . Women childbearing potential must negative pregnancy test prior randomization . Women childbearing potential may still participate trial must plan become pregnant course study must practice suitable method birth control . If patient becomes pregnant begin breastfeed study , study drug discontinue immediately , patient follow duration study Evidence contraindication use Trial Medication : ( ) serious systemic bleeding preclude antiplatelet therapy ; ( ii ) hypersensitivity aspirin , thienopyridine drug ( clopidogrel ticlopidine ) statins ; ( iii ) current past history renal insufficiency [ serum Creatinine &gt; 150 umol ] ; ( iv ) hepatic dysfunction indicate follow [ ALT &gt; 3xULN , AST &gt; 3xULN , ALP &gt; 3xULN ] ; ( v ) thrombocytopenia [ platelet count &lt; 150 x10^9/L ] ; ( vi ) neutropenia [ neutrophil count &lt; 0.5 x10^9/L ] ; ( vii ) bleed diathesis coagulopathy indicate follow [ INR &gt; 1.2 , PT &gt; 1.2xULN , PTT &gt; 1.2xULN ] Life expectancy le 90 day Participation another clinical therapeutic trial ( drug device ) either concurrently within previous 30 day , prior participation FASTER Geographical factor render followup impractical render evaluation outcome event impossible ( e.g . severe dementia ) . Patients may randomize could willing complete followup participate centre</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Transient Ischemic Attack</keyword>
	<keyword>Stroke</keyword>
	<keyword>Stroke Prevention</keyword>
	<keyword>Recurrence</keyword>
	<keyword>Neuroprotection</keyword>
	<keyword>Antiplatelet Therapy</keyword>
	<keyword>Statins</keyword>
</DOC>